Markets:

Overview

News

Currencies

International

Treasuries

COMPASS Pathways Plc - American Depository Shares (NQ:CMPS)

6.680 +0.120 (+1.83%)

Streaming Delayed Price Updated: 12:33 PM EST, Jan 6, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about COMPASS Pathways Plc - American Depository Shares

< Previous 1 2 3 4 5 6 7 8 9

...

27 28 Next >

Psychedelics Break Out Of The Fringe Under RFK Jr’s 2025 Reset — But Did MNMD Or CMPS Own The Year? ↗

December 24, 2025

Regulatory thaw, political backing, and late-stage data are propelling psychedelic drugmakers into the biotech spotlight — with Compass Pathways and Mind Medicine leading the charge.

Via Stocktwits

Topics ETFs

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

November 04, 2025

Via Benzinga

Earnings Scheduled For November 4, 2025 ↗

November 04, 2025

Via Benzinga

Compass (CMPS) Q2 Loss Improves 27% ↗

August 01, 2025

Via The Motley Fool

Earnings Scheduled For July 31, 2025 ↗

July 31, 2025

Via Benzinga

These 2 Stocks Could More Than Double Your Money, According to Wall Street. Is It Time to Buy? ↗

July 20, 2025

Via The Motley Fool

Earnings Scheduled For May 8, 2025 ↗

May 08, 2025

Via Benzinga

Stifel Says Compass Pathways Selloff 'Significantly Overdone' After Psilocybin Trial Data ↗

June 24, 2025

The company is also conducting a second Phase 3 study evaluating the effects of two doses of COMP360 given three weeks apart.

Via Stocktwits

What's going on in today's session ↗

June 23, 2025

Curious about what's happening in today's session? Check out the latest stock movements and price changes.

Via Chartmill

Compass Pathways Stock Is Plunging Today: What's Going On? ↗

June 23, 2025

COMPASS Pathways Plc (NASDAQ:CMPS) stock is trading lower on Monday. The company announced it reached its primary endpoint in the ongoing Phase 3 COMP005 trial, but results may have not met lofty...

Via Benzinga

12 Health Care Stocks Moving In Monday's Intraday Session ↗

June 23, 2025

Via Benzinga

Compass Pathways Stock Slumps After Positive Late-Stage Trial Results From Psychedelic Drug ‘Underwhelm’ Analysts ↗

June 23, 2025

The company said it will discuss the “highly statistically significant and clinically meaningful” data with the U.S. Food and Drug Administration, which has yet to review it.

Via Stocktwits

Crude Oil Falls 1%; US Services PMI Declines In June ↗

June 23, 2025

Via Benzinga

Which stocks are experiencing notable movement on Monday? ↗

June 23, 2025

Stay up-to-date with the latest market trends in the middle of the day on Monday. Explore the top gainers and losers during today's session in our detailed report.

Via Chartmill

Why Is Compass Pathways Stock Trading Lower On Monday? ↗

June 23, 2025

Compass Pathways' COMP005 trial met its primary endpoint in TRD, but modest results sparked a 47% drop in shares amid investor disappointment

Via Benzinga

Dow Jumps Over 200 Points; FactSet Research Shares Gain After Q3 Results ↗

June 23, 2025

Via Benzinga

Topics Stocks

These stocks are gapping in today's session ↗

June 23, 2025

There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Monday.

Via Chartmill

These stocks are moving in today's pre-market session ↗

June 23, 2025

Discover the top movers in Monday's pre-market session and stay informed about market dynamics.

Via Chartmill

Vizsla Silver, COMPASS Pathways And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗

June 23, 2025

Via Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

June 23, 2025

Via Benzinga

Why Sequans Communications Shares Are Trading Higher By Over 42%; Here Are 20 Stocks Moving Premarket ↗

June 23, 2025

Via Benzinga

Adobe, FibroGen And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗

June 13, 2025

Via Benzinga

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

June 12, 2025

Via Benzinga

Ex-Gov't Foe Joins Trump, RFK Jr.'s HHS To Lead Psychedelics Policy: What It Means For Investors ↗

May 24, 2025

Psychedelics litigator Matthew Zorn joins HHS under RFK Jr. to lead policy. What it means for CMPS, MNMD, CYBN, PSIL & more.

Via Benzinga

Topics Government

Agilysys, Amer Sports, X Financial And Other Big Stocks Moving Higher On Tuesday ↗

May 20, 2025

Via Benzinga

Why Compass Pathways Stock Was a Double-Digit Winner This Week ↗

April 25, 2025

Via The Motley Fool

Mind Medicine's Net Losses Swell In Q4, But Retail Finds At Least 3 Reasons To Stay Bullish ↗

March 06, 2025

The psychedelics treatment developer reported a net loss of $34.7 million for the quarter ended Dec. 31, 2024, widening from a $23.8 million loss a year earlier.

Via Stocktwits

Psychedelics-Focused Compass Pathways Has Established Itself As 'Credible CNS Biotechnology Company,' Analyst Says ↗

February 27, 2025

Compass Pathways gains Stifel's Buy rating as its COMP360 psilocybin treatment advances in Phase 3 trials. Key depression study data expected in 2025-2026.

Via Benzinga

Compass Pathways Plc (CMPS) Q4 2024 Earnings Call Transcript ↗

February 27, 2025

CMPS earnings call for the period ending December 31, 2024.

Via The Motley Fool

Topics Earnings

This Plumas Bancorp Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Thursday ↗

February 27, 2025

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

27 28 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.